Oral News and Research

RSS

Watson Pharmaceuticals files application for generic LYBREL

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg) extended-cycle oral contraceptive product prior to the expiration of patents owned by Wyeth.

14 Mar 2008

New clues to prevent spread of ovarian cancer

A drug that blocks production of an enzyme that enables ovarian cancer to gain a foothold in a new site can slow the spread of the disease and prolong survival in mice, according to a study by researchers from the University of Chicago Medical Center, but only if the drug is given early in the disease process.

14 Mar 2008

Oral methadone dosing for chronic pain: practitioner's guide

Methadone, a strong opioid analgesic, is an effective and economical choice for the management of cancer pain and chronic noncancer pain, both as a first line medication and as a replacement opioid.

14 Mar 2008

Watch your teeth if drinking energy drinks

For more than 10 years, energy drinks in the United States have been on the rise, promising consumers more "oomph" in their day.

13 Mar 2008

Diabetes and dental health

People who live with diabetes on a daily basis are usually instructed to eat right, maintain regular physical activity, and if necessary, take medication.

13 Mar 2008

Aerosol vaccine provides low-cost, needle-free TB treatment

A novel aerosol version of the most common tuberculosis (TB) vaccine, administered directly to the lungs as an oral mist, offers significantly better protection against the disease in experimental animals than a comparable dose of the traditional injected vaccine, researchers report this week in the Proceedings of the National Academy of Sciences.

13 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

New behavioral risk factors for head and neck cancers

Researchers at the Johns Hopkins Kimmel Cancer Center have teased out two distinct sets of risk factors for head and neck cancers, suggesting that there are two completely different kinds of the disease.

12 Mar 2008

Researchers develop system that understand spoken language

A research team drawn from the Department of Systems and Automation Engineering of the Polytechnic University School and from the Faculty of Informatics at the Donostia-San Sebastian campus of the University of the Basque Country (UPV/EHU) and led by lecturer Miren Karmele Lopez de Ipina, is developing systems that process and understand spoken language and automatically obtain information particularly from Basque radio and television.

11 Mar 2008

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center.

11 Mar 2008

Long-term effects of synthetic progestins cause for concern

The widely used synthetic progestin medroxyprogesterone acetate (MPA) decreased endothelial function in premenopausal women in a study done at the University of Oregon.

11 Mar 2008

Tackling antimicrobial resistance

Drug resistance is making many diseases increasingly difficult and sometimes impossible to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

11 Mar 2008

Discovery of new way to control growth rate of replacement tissue and formation of new blood vessels

Researchers have discovered a way to control the growth rate of replacement tissue and the formation of new blood vessels, which solves one of the vexing problems of growing replacement tissue to treat injuries and trauma in humans.

10 Mar 2008

Watson Pharmaceuticals files application for generic SEASONIQUE

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc.

6 Mar 2008

New malaria drug also treats toxoplasmosis

A new drug that will soon enter clinical trials for treatment of malaria also appears to be 10 times more effective than the key medicine in the current gold-standard treatment for toxoplasmosis, a disease caused by a related parasite that infects nearly one-third of all humans—more than two billion people worldwide.

6 Mar 2008

New research aims to eliminate Streptococcus infections

Professor Howard Jenkinson in the Department of Oral & Dental Science (Dental School) at the University of Bristol has been awarded a grant of £285,000 from The Wellcome Trust to research ways to combat diseases caused by Streptococcus bacteria.

5 Mar 2008

Guidelines for von Willebrand disease diagnosis and management

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

4 Mar 2008

Barr Pharmaceuticals announces favorable ruling in Yasmin patent case

Barr Pharmaceuticals, Inc. has announced that the U.S. District Court for the District of New Jersey has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Bayer Schering Pharma, AG in connection with Bayer Schering's Yasmin(R) (drospirenone and ethinyl estradiol) oral contraceptive.

4 Mar 2008

New nanotube findings give boost to potential biomedical applications

Carbon nanotubes have shown real promise as highly accurate vehicles for delivering antitumor agents into malignant cells, but a dearth of data about what happens to the tubes after they discharge their medical payloads has been a major stumbling block to progress.

3 Mar 2008

National Institute for Health and Clinical Excellence (NICE) releases appraisal consultation document on treatment of pulmonary arterial hypertension in adults

The National Institute for Clinical Excellence (NICE) has published on its website the preliminary recommendations of its Appraisal Committee on the use of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of pulmonary hypertension in adults.

3 Mar 2008